In Brief: Generic OTC minoxidil
Generic OTC minoxidil: Lemmon and Barre-National gain ANDA approvals for minoxidil 2% April 5, the same week Pharmacia & Upjohn launches its OTC version of Rogaine. FDA approved the generics following a decision not to grant Pharmacia & Upjohn the three-year marketing exclusivity it had requested for the OTC switch ("The Pink Sheet" Feb. 12, T&G-12). Bausch & Lomb, which along with Lemmon previously had gained tentative ANDA approvals for generic minoxidil, has not yet received final approval. The generics are approved only for OTC use in male pattern baldness. The generic firms must submit stability data on minoxidil packaged in the applicator used in female alopecia to gain approval for that indication...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth